Data / Form D filings / Hubble Therapeutics, LLC
Hubble Therapeutics, LLC: Form D filing
Hubble Therapeutics, LLC, a biotechnology company in Hanover, NH, filed a Form D with the SEC in 2024. The latest, on October 21, 2024, reports $9.8 million sold of a $11.1 million offering to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 35 SOUTH MAIN STREET, Hanover, NH, 03755
- Phone
- (617) 780-2375
- Industry
- Biotechnology
- Entity type
- Limited Liability Company
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2038883
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2024 | New notice | $11,107,697 | $9,807,697 | $1,300,000 | 17 | Oct 9, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jeff Sabados | Executive Officer, Director | |
| Sam Goldberger | Director | |
| Greg Keenan | Director |
Every Form D from the week of Oct 21, 2024 · All recent filings in New Hampshire · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Hubble Therapeutics, LLC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.